Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
In fact, Johnson & Johnson is one of the companies that is part of the exclusive dividend kings. The company has been increasing its dividend for 62 consecutive years, and the company's rock-solid ...
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer patients.
JNJ ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Johnson & Johnson Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible v...
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Medicine is the cornerstone of healthcare. That remains true today, with a global pharmaceutical industry valued at $1.4 trillion and expected to grow at 6.1% annually through 2030.
Trellus Health shares jump 180% on Johnson & Johnson collaboration
Shares in Trellus Health PLC (AIM:TRLS) soared 180% after the company announced a collaboration with Johnson & Johnson (NYSE:JNJ) Health Care Systems Inc. The partnership will pilot Trellus Health'...
2 Beaten-Down Dividend Stocks to Buy in 2025
Dividend stocks are great for various reasons, and it's even better to invest in them while they are going through a rough patch, provided there are good reasons to believe they will recover. This ...
Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies
Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the deal would mark the largest biotech acquisitio...
Johnson & Johnson Could Serve As High-Yield Bond Alternative
Johnson & Johnson remains a "Buy" for its stability and consistent dividends, despite short-term price fluctuations and modest growth expectations. Q3 2024 results showed a 5.2% sales increase but ...
JNJ ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Johnson & Johnson investment
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible v...
Johnson & Johnson: A Potential Beneficiary Of A Great Rotation
Johnson & Johnson's stagnant price and bond-like behavior make it an income investment, but a market shift could boost its appeal in 2025. Value stocks, including JNJ, may gain favor as growth stoc...
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
2 Dividend Kings to Rule Them All in 2025
If history is any teacher, the best thing you can do with your money is buy dividend stocks.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Johnson & Johnson (JNJ) settling at $144.62, representing a +0.89% change from its previous close.
J&J Trading Near 52-Week Low: Should You Sell the Stock?
Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.
Related Companies